Furthermore, in vitro and in vivo experimental validation offered convincing evidence that GSZD may partially attenuate RA by reversing inflammation-immune system imbalance and regulating the HDAC1–HSP90AA1–NFKB2–IKBKB–TNF-α signaling axis. The gene discussed is NFKB2; the disease is rheumatoid arthritis.